<DOC>
	<DOCNO>NCT02099175</DOCNO>
	<brief_summary>Sinonasal tumor rare disease , standard treatment aggressive tumor report , give rarity , absence prospective study heterogeneity histology stag disease . This study propose innovative integration multiple modality treatment depend histology , molecular profile response induction CT . Moreover , strategy allow use late technology great biological effectiveness reduction toxicity .</brief_summary>
	<brief_title>Multidisciplinary Approach Poor Prognosis Sinonasal Tumors Operable Patients</brief_title>
	<detailed_description>So far , surgery follow radiotherapy ( RT ) usual approach advance disease . Technical improvement surgical approach report , provide less invasive surgery low morbidity . In scenario , multimodality treatment seem best approach , even lack prospective data . Some study explore role feasibility induction chemotherapy ( CT ) prognostic value response CT. Histology molecular pattern guide type administer CT . The first drive choice drug associate Cisplatin , mutational status p53 ( wild type , WT v mutate , MUT ) predictive value response CT Cisplatin plus 5-Fluorouracil Leucovorin ITAC . In addition , heavy ion therapy may produce less toxic side effect particularly critical area expose late RT toxicity potentially help organ preservation strategy exenteratio orbitae request .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Signed date IECapproved Informed Consent 2 . Diagnosis sinonasal tumor follow histotypes : Squamous Cell Carcinoma ( SCC ) ; Sinonasal Undifferentiated Carcinoma ( SNUC ) ; Small Cell Carcinoma Neuroendocrine Type ( SmCCNET ) ; Pure Sinonasal Neuroendocrine Carcinoma ( SNEC ) ; Intestinal Type Adenocarcinoma ( ITAC ) functional p53 gene ; Esthesioneuroblastoma differentiation grade IIIIV Hyams The inclusion maxillary sinus carcinoma reserve case require exenteratio orbitae radical surgery . 3 . AJCC stage IIIIIIVa exception Esthesioneuroblastoma Intestinal Type Ethmoid Adenocarcinoma stage IIIIV include . 4 . Resectable disease . 5 . ECOG performance status 02 . 6 . Adequate bone marrow , renal hepatic functionality , define haemoglobin &gt; 10 g/dL , neutrophils &gt; 1500/mmc , platelet &gt; 100.000/mmc , creatinine value ≤ 1.5 x ULN calculate creatinine clearance ( Cockcroft Gault 's formula ) &gt; 60 mL/min , transaminases value &lt; 1.5 time upper normal limit ( ULN ) . 7 . Polychemotherapy treatment clinical feasibility per Investigator 's Judgment . 8 . Male female patient ≥ 18 year age . 9 . Negative pregnancy test ( female reproductive year ) . 10 . Agreement upon use effective contraceptive method ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation , men woman child produce potential . 1 . Previous radiotherapy chemotherapy head neck district tumor ( surgical treatment relapse admit ) . 2 . Metastatic disease . 3 . Cardiac , pulmonary , infective , neurological disease medical condition could interfere treatment . 4 . Unable unwilling comply schedule visit , therapy plan , laboratory test require protocol . 5 . Previous diagnosis malignant neoplasm last 3 year ( situ cervical cancer completely excise basocellular/squamocellular skin cancer always admit ) . 6 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation may interfere interpretation study result , judgment Investigator , would make patient inappropriate entry study could compromise protocol objective opinion Investigator and/or Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>